Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps.
about
Advances in inhalation dosimetry models and methods for occupational risk assessment and exposure limit derivationSpatio-temporal simulation of first pass drug perfusion in the liverUrinary, circulating, and tissue biomonitoring studies indicate widespread exposure to bisphenol AA mechanistic, model-based approach to safety assessment in clinical developmentA physiologically based pharmacokinetic model for the oxime TMB-4: simulation of rodent and human data.Reconstruction of Exposure to m-Xylene from Human Biomonitoring Data Using PBPK Modelling, Bayesian Inference, and Markov Chain Monte Carlo Simulation.A Workflow for Global Sensitivity Analysis of PBPK Models.In silico toxicology - non-testing methods.Quantitative global sensitivity analysis of a biologically based dose-response pregnancy model for the thyroid endocrine system.Approaches for applications of physiologically based pharmacokinetic models in risk assessment.Urinary, circulating, and tissue biomonitoring studies indicate widespread exposure to bisphenol A.Evolution of chemical-specific adjustment factors (CSAF) based on recent international experience; increasing utility and facilitating regulatory acceptance.Performance Assessment and Translation of Physiologically Based Pharmacokinetic Models from acslX™ to Berkeley Madonna™, MATLAB®, and R language: Oxytetracycline and Gold Nanoparticles as Case Examples.MEGen: A Physiologically Based Pharmacokinetic Model Generator.A Risk Assessment Perspective of Current Practice in Characterizing Uncertainties in QSAR Regression Predictions.Modeling Pharmacokinetics.In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions.Development and application of a human PBPK model for bromodichloromethane to investigate the impacts of multi-route exposure.Physiologically based toxicokinetic modelling as a tool to support risk assessment: three case studies.A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks.Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications.Enhanced QSAR model performance by integrating structural and gene expression information.QSARs for PBPK modelling of environmental contaminants.A physiologically based toxicokinetic modelling approach to predict relevant concentrations for in vitro testing.Challenges Associated with Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making.Good modeling practice guidelines for applying multimedia models in chemical assessments.Development and validation of a physiology-based model for the prediction of pharmacokinetics/toxicokinetics in rabbits.Parameter Estimation Using Unidentified Individual Data in Individual Based Models
P2860
Q23912442-D7BD3735-C4FD-45D7-BDED-CD204FEAD446Q27322901-3B730A1B-C2EC-4A63-8751-D43B300435D5Q28382768-3A4F082E-007F-4F6D-A422-9CEAA961C267Q28395802-4C16ECCB-70D4-49EF-A461-09A45F261D56Q30585790-B479F955-175B-40EA-BBC2-7F95C16D341EQ34311634-633ACA95-7500-410D-AAE7-33CE42CEE72EQ35084469-8D1F5265-92EC-4644-AE55-5DAF2FA7DB74Q35084668-9A2C8D4E-3E32-43C2-ABCF-ABEA6B4CA20CQ35650275-9BB31D74-7CCA-4F0D-9500-81B1758C5D65Q37201545-1EE0A161-79C9-41D8-9A0D-743F91702398Q37977848-6356068F-F04E-4C68-B977-04BC515D019AQ38691542-E2D307F4-9758-4A63-B446-A159733B8414Q38731345-B348F256-AB2C-495A-B09B-FB368B1D575CQ39017720-89212139-0091-4558-A3F3-3D7D63EABFDEQ39551017-ED7A0C41-6974-4AF4-89FF-A8B9E1D9AC31Q39677925-8676EDC0-19E1-4F0E-9144-9E9168BED5EEQ39730914-C7358911-6F52-4FA6-B7AB-29EBC4416947Q40230063-61FFDCD7-E542-41A8-B669-77B9407C577CQ41850809-349E6765-DBAA-4887-B2B1-830E8515CD24Q42018625-A4F2E7AD-C6FC-4AA9-92BE-EB6C85DDF7FCQ42633014-228127BA-66F9-45F9-AA4B-55B7A59A60DBQ44486876-5D61E975-776A-41DA-8FFD-0949D5D2FA6DQ45995747-8C0FE118-AB3F-4412-83F8-B5CCD85B2257Q46342214-F11D8BB9-D638-4AD4-B5BA-CFD2678572A2Q49551649-DCDB16B2-AAEC-4926-A096-E714AC9426A0Q53667384-7D1A0086-E011-4CBD-8600-1FC4572B54CEQ55032467-FA61A1F1-DF8F-4ECD-A401-E22EB13E7503Q57433873-3F1E0FA0-C21E-4B55-B7C5-C767CB429D87
P2860
Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of good modelling ...... k assessment: the first steps.
@en
Development of good modelling ...... k assessment: the first steps.
@nl
type
label
Development of good modelling ...... k assessment: the first steps.
@en
Development of good modelling ...... k assessment: the first steps.
@nl
prefLabel
Development of good modelling ...... k assessment: the first steps.
@en
Development of good modelling ...... k assessment: the first steps.
@nl
P2093
P50
P1476
Development of good modelling ...... k assessment: the first steps.
@en
P2093
Bette Meek
George Loizou
Gerhard Goerlitz
Harvey J Clewell
Hugh A Barton
Martin Spendiff
Michel Bouvier d'Yvoire
Ursula Gundert-Remy
P304
P356
10.1016/J.YRTPH.2008.01.011
P407
P577
2008-02-01T00:00:00Z